Skip to main
SLDB
SLDB logo

Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences (SLDB) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 64%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Solid Biosciences Inc. demonstrates a positive outlook based on encouraging reductions in clinical biomarkers of muscle damage in Duchenne muscular dystrophy patients, indicating improved muscle integrity. The initial results from the INSPIRE DUCHENNE study reveal strong vector transduction and microdystrophin expression, along with promising early signs of cardiac benefits, contributing to optimism regarding the efficacy of its pipeline products. Additionally, the favorable safety profile of SGT-003, highlighted by the absence of serious adverse events, further underscores the company's potential for successful market entry in a therapeutic area with significant unmet need.

Bears say

Solid Biosciences Inc faces significant risks regarding the regulatory approval of its lead product, SGT-003, which could lead to downward revisions in risk-adjusted projections and financial forecasts, even if clinical endpoints are met. Additionally, the company must enhance its manufacturing capacity to avoid constraints on SGT-003 sales, which poses further challenges to achieving projected revenue targets. These factors contribute to a negative outlook for the company's stock, as they highlight potential setbacks in both regulatory and operational capabilities.

Solid Biosciences (SLDB) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 64% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solid Biosciences (SLDB) Forecast

Analysts have given Solid Biosciences (SLDB) a Buy based on their latest research and market trends.

According to 11 analysts, Solid Biosciences (SLDB) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solid Biosciences (SLDB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.